相关实验视频

Updated: Jul 26, 2025

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

lncRNAs-EZH2相互作用作为皮肤黑色素瘤的有希望的治疗点

Michal Wozniak¹, Malgorzata Czyz¹

¹Department of Molecular Biology of Cancer, Medical University of Lodz, Lodz, Poland.

Frontiers in molecular biosciences

|June 16, 2023

概括

长非编码RNAs (lncRNAs) 是黑色素瘤中EZH2-介导基因沉默的关键调节者. 针对lncRNAs和EZH2之间的相互作用可能为这种致命的皮肤癌提供一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.

背景情况:

全球黑色素瘤发病率正在上升,尽管诊断和治疗方面取得了进展,但这仍是一个重大的临床挑战.
增强Zeste同类基因2 (EZH2) 的增强剂,是多抑制综合体2 (PRC2) 的组成部分,在表观遗传基因沉默中起着至关重要的作用.
由激活突变驱动的异常EZH2活性,有助于在黑色素瘤进展期间抑制基因沉默.

研究的目的:

审查目前对长非编码RNAs (lncRNAs) 在黑色素瘤中EZH2-介导的基因沉默的理解.
探索针对黑色素瘤治疗中的lncRNA-EZH2相互作用的治疗潜力.
讨论与这种治疗方法相关的潜在挑战和争议.

主要方法:

关于lncRNAs,EZH2和黑色素瘤的当前研究的文献综述.
分析lncRNAs作为EZH2-介导表观遗传沉默的特异性因素的作用.
讨论针对 lncRNA-EZH2 相互作用的治疗策略.

主要成果:

lncRNAs充当"地址代码",将EZH2引导到特定的基因组位置以进行沉默.
对lncRNA-EZH2相互作用的失调有助于黑色素瘤的发病.
针对这些相互作用为新型黑色素瘤疗法提供了一个有希望的途径.

结论:

lncRNAs是EZH2在黑色素瘤中的功能不可或缺的一部分,影响基因表达模式.
抑制lncRNA-EZH2相互作用提供了一个潜在的治疗策略,以阻碍黑色素瘤的进展.
需要进一步的研究来解决这种方法的复杂性和潜在缺点.

关键词:

在 EZH2 中使用.在 PRC2 中,PRC2 是 PRC2 的第一个类型.表观遗传学是指表观遗传学.免疫疗法免疫疗法在 lncRNAs 中.黑色素瘤是一种黑色素瘤.有针对性的治疗.

更多相关视频

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Identification of Transcription Factor Regulators using Medium-Throughput Screening of Arrayed Libraries and a Dual-Luciferase-Based Reporter

Published on: March 27, 2020

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...